EYPT

Business Context and Reporting Period

Company: pSivida Corp. (Note: Request metadata listed "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: December 31, 2010
Business Overview: pSivida develops sustained-release drug delivery products for chronic eye diseases using Durasert and BioSilicon technologies. Key assets include ILUVIEN (licensed to Alimera Sciences), Retisert, and Vitrasert (licensed to Bausch & Lomb).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 87% to $0.89 million. This was primarily due to the completion of the 21.5-month performance obligation period for the Alimera collaboration agreement in December 2009, which previously generated significant amortized revenue.
• Operating Expenses: Total operating expenses increased 6% to $7.45 million. General and administrative expenses rose 19% due to increased professional fees and stock-based compensation. Research and development expenses decreased 7% to $3.28 million, partially offset by a $0.21 million federal grant.
• Derivative Income: The company recorded $0.80 million in income from the change in fair value of derivative liabilities (A$-denominated warrants), compared to a $1.44 million expense in the prior year. This shift was driven by the spread between the share price and exercise price and the short remaining life of the warrants.
• Cash Flow: Net cash used in operating activities increased to $2.80 million. Investing activities consumed $5.34 million, primarily for the purchase of marketable securities.

Guidance, Outlook, and Risks

• ILUVIEN Regulatory Status: The FDA issued a Complete Response Letter (CRL) in December 2010 regarding the New Drug Application (NDA) for ILUVIEN, stating it could not be approved in its present form. The FDA requested additional safety/efficacy analyses through month 36 and information on manufacturing controls. Alimera intends to submit this data by the end of Q1 2011.
• Liquidity Outlook: Management believes existing capital resources ($14.6 million) combined with approximately $10.1 million raised in a January 2011 registered direct offering will fund operations into at least calendar year 2013.
• Future Revenue Dependency: Future profitability is heavily dependent on FDA approval of ILUVIEN, which would trigger a $25.0 million milestone payment from Alimera. Absent approval, collaborative revenue is expected to be insignificant.
• Risk Factors: Significant risks include the uncertainty of ILUVIEN approval, potential impairment of intangible assets ($22.7 million carrying value), fluctuations in derivative liability valuations, and the need for additional capital if milestones are not met.

Investor Verification Checklist

• ILUVIEN Submission: Verify the status of Alimera's resubmission of the 36-month clinical data to the FDA and any subsequent FDA communications.
• Capital Position: Confirm the net proceeds from the January 2011 registered direct offering and the company's burn rate to validate the "funding through 2013" assertion.
• Derivative Liability: Monitor the fair value of A$-denominated warrants, as fluctuations in the share price and exchange rates will continue to impact non-cash earnings until expiration in July 2012.
• Intangible Assets: Review the valuation of the $22.7 million in intangible assets (BioSilicon and Durasert) for potential impairment charges if ILUVIEN approval is delayed or denied.
• Royalty Trends: Assess the declining royalty income from Bausch & Lomb (Retisert/Vitrasert) and its impact on baseline cash flow.